The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease

Glucocorticosteroids are the mainstay of treatment of active Crohn's disease and ulcerative colitis. These drugs however carry important cosmetic short-term side effects and when used long-term they induce severe irreversible complications. Topically acting glucocorticosteroids, especially bude...

Full description

Saved in:
Bibliographic Details
Main Author: P. Rutgeerts
Format: Article
Language:English
Published: Wiley 1998-01-01
Series:Mediators of Inflammation
Subjects:
Online Access:http://dx.doi.org/10.1080/09629359891036
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832545409474494464
author P. Rutgeerts
author_facet P. Rutgeerts
author_sort P. Rutgeerts
collection DOAJ
description Glucocorticosteroids are the mainstay of treatment of active Crohn's disease and ulcerative colitis. These drugs however carry important cosmetic short-term side effects and when used long-term they induce severe irreversible complications. Topically acting glucocorticosteroids, especially budesonide, have been designed to achieve local effect at the site of inflammation without systemic effects of the drug. The first results of clinical trials are promising and budesonide has been shown to have an improved safety with almost comparable efficacy in comparison with prednisolone. The optimal enema dose seems to be 2 mg/100 ml at night whereas 9 mg o.m. is the optimal dose to treat ileal or right ileocolonic Crohn's disease. Topically acting GCS, like standard GCS are not effective for maintenance of remission of Crohn's disease or recurrence prevention after resection of the involved Crohn's segment.
format Article
id doaj-art-eec91961d12340b48d6090abe7560abd
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 1998-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-eec91961d12340b48d6090abe7560abd2025-02-03T07:26:05ZengWileyMediators of Inflammation0962-93511466-18611998-01-017313714010.1080/09629359891036The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel diseaseP. Rutgeerts0Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, Leuven 3000, BelgiumGlucocorticosteroids are the mainstay of treatment of active Crohn's disease and ulcerative colitis. These drugs however carry important cosmetic short-term side effects and when used long-term they induce severe irreversible complications. Topically acting glucocorticosteroids, especially budesonide, have been designed to achieve local effect at the site of inflammation without systemic effects of the drug. The first results of clinical trials are promising and budesonide has been shown to have an improved safety with almost comparable efficacy in comparison with prednisolone. The optimal enema dose seems to be 2 mg/100 ml at night whereas 9 mg o.m. is the optimal dose to treat ileal or right ileocolonic Crohn's disease. Topically acting GCS, like standard GCS are not effective for maintenance of remission of Crohn's disease or recurrence prevention after resection of the involved Crohn's segment.http://dx.doi.org/10.1080/09629359891036glucocorticosteroidsCrohn's diseaseulcerative colitis budesomideprednisoloneremission.
spellingShingle P. Rutgeerts
The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
Mediators of Inflammation
glucocorticosteroids
Crohn's disease
ulcerative colitis
budesomide
prednisolone
remission.
title The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
title_full The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
title_fullStr The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
title_full_unstemmed The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
title_short The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
title_sort use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
topic glucocorticosteroids
Crohn's disease
ulcerative colitis
budesomide
prednisolone
remission.
url http://dx.doi.org/10.1080/09629359891036
work_keys_str_mv AT prutgeerts theuseoforaltopicallyactingglucocorticosteroidsinthetreatmentofinflammatoryboweldisease
AT prutgeerts useoforaltopicallyactingglucocorticosteroidsinthetreatmentofinflammatoryboweldisease